The company recently reported another strong quarter, showcasing what it described as "top tier performance" during its Q1 earnings call. The results underline the firm's ability to leverage its robust pipeline, which continues to offer a steady stream of growth opportunities.
Looking ahead, the company has indicated that foreign exchange fluctuations are likely to pose a challenge, projecting a 1% negative impact on sales for the fiscal year 2025. Despite this hurdle, the company's strategic focus on growth initiatives remains a key priority, suggesting continued resilience in an unpredictable market environment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Abbott Laboratories (ABT, Financial) is $136.76 with a high estimate of $158.00 and a low estimate of $111.34. The average target implies an upside of 5.45% from the current price of $129.70. More detailed estimate data can be found on the Abbott Laboratories (ABT) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Abbott Laboratories's (ABT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Abbott Laboratories (ABT, Financial) in one year is $118.41, suggesting a downside of 8.7% from the current price of $129.695. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Abbott Laboratories (ABT) Summary page.
